A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors

AIDS

Volumn 17, Issue 1, 2003, Pages

  Brenner, Bluma ^a   Turner, Dan ^a   Oliveira, Maureen ^a   Moisi, Daniela ^a   Detorio, Mervi ^a   Carobene, Mauricio ^a   Marlink, Richard G ^b,c   Schapiro, Jonathan ^d   Roger, Michel ^e   Wainberg, Mark A ^a  

^a MCGILL UNIVERSITY   (Canada)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c Botswana Harvard Laboratory   (Botswana)

^d STANFORD UNIVERSITY   (United States)

^e Dept de Microbiol et d'Immunologie ^*  (Canada)

Author keywords

Clade C; Efavirenz; HIV 1; Non nucleoside reverse transcriptase inhibitors

Indexed keywords

DELAVIRDINE; EFAVIRENZ; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VALINE;

ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL ARTICLE; CODON; CROSS RESISTANCE; DRUG EXPOSURE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MUTATION; PHENOTYPE; PRIORITY JOURNAL; VIRUS ISOLATION;

ANTI-HIV AGENTS; CULTURE TECHNIQUES; DRUG RESISTANCE, VIRAL; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MUTATION; OXAZINES; PHENOTYPE; POLYMORPHISM, GENETIC; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0037415062     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200301030-00001     Document Type: Article

References (21)

1. Pallela FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998, 338:853-860.
2. Loemba H, Brenner B, Parniak MA, Ma'ayan S, Spira B, Moisi D, et al. Genetic divergence of HIV-1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against non-nucleoside inhibitors of RT. Antimicrob Agents Chemother 2002, 46:2087-2094.
3. Loemba H, Wainberg MA, Brenner BG. Effects of HIV-1 clade diversity on HIV-1 virulence and antiretroviral drug sensitivity. Recent Rev Devel Virol 2001, 3:121-129.
4. Pillay D, Walker AS, Gibb DM, de Rossi S, Kaye M, Ait-Khaled M, et al. Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 Trial. J Infect Dis 2002, 186:617-625.
5. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 1999, 341:1865-1872.
6. Robbins G, Shafer R, Smeaton L, de Grottola V, Pettinelli C, Synder S, et al. Antiretroviral strategies in naive HIV+ subjects: comparisons of sequential 3-drug regimens (ACTG 384). Program and abstracts of the XIV International Conference on AIDS. Barcelona, July 7-12, 2002 [abstract LbOr20A].
7. Loemba H, Brenner B, Parniak MA, Ma'ayan S, Spira B, Moisi D, et al. Polymorphisms of cytotoxic T-lymphocyte (CTL) and T-helper epitopes within reverse transcriptase (RT) of HIV-1 subtype C from Ethiopia and Botswana following selection of drug resistance. Antiviral Res 2002, 56:129-142.
8. Shafer RW, Gonzales MJ, Brun-Vezinet F. Online comparison of HIV-1 drug resistance algorithms identifies rates and causes of discordant interpretations. Antiviral Ther 2001, 6 (suppl 1):101.
9. Gu Z, Gao Q, Li X, Parniak MA, Wainberg MA. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine. J Virol 1992, 66:7128-7135.
10. Salomon H, Wainberg MA, Brenner BG, Quan Y, Rouleau D, Cote P, et al. Prevalence of HIV-1 viruses resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or intravenous drug use. AIDS 2000, 14:F17-F23.
11. Hammond J, Larder BA, Schinasi RF, Mellors JW. Mutations in retroviral genes associated with drug resistance. http://www.hiv.lanl.gov/HTML/reviews/Mellors.html
12. Advanced Biological Laboratories Website. http://www.ablnet works.com
13. Beerenwinkel N, Schmidt B, Walter H, Kaiser R, Lengauer T, Hoffmann D, et al. Diversity and complexity of HIV-1 drug resistance: A bioinformatics approach to predicting phenotype from genotype. Proc Natl Acad Sci, USA 2002, 99:8271-8276.
14. D'Aquila RT, Schapiro JM, Brun-Vezinet F, Clotet B, Conway B, Demeter LM, et al. Drug resistance mutations in HIV-1. Topics in HIV Med 2002, 10:21-25.
15. Frater AJ, Beardall A, Ariyoshi K, Churchill D, Galpin S, Clarke JR, et al. Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients. AIDS 2001, 15:1493-1502.
16. Palmer S, Alaeus A, Albert J, Cox S. Drug susceptibility of subtypes A, B, C, D, and E human immunodeficiency virus type 1 isolates. AIDS Res Hum Retroviruses 1999, 14:157-162.
17. Caride E, Hertogs K, Larder B, Dehertogh P, Brindeiro R, Machado E, et al. Genotypic and phenotypic evidence of different drug-resistance mutation patterns between B and non-B subtype isolates of human immunodeficiency virus type 1 found in individuals failing HAART. Virus Genes 2001, 23:193-202.
18. Caride E, Brindeiro R, Hertogs K, Larder B, Dehertogh P, Machado E, et al. Drug-resistant reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of human immunodeficiency virus type 1 found in Brazilian patients failing HAART. Virology 2000, 275:107-115.
19. Loveday C, van Hooff F, Johnson M. Inferior virological response to highly active antiretroviral therapy in patients with HIV-1 subtype C infection: a case controlled study. Antiviral Ther 2002, 7:S145.
20. Archer RH, Dykes C, Gerondelis P, Lloyd A, Fay P, Reichman RC, et al. Mutants of human immunodeficiency virus type (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RnaseH cleavage that correlate with HIV-1 replication fitness in cell culture. J Virol 2000, 74:8390-8401.
21. Bacheler LT, Anton ED, Kudish, P, Baker D, Bunville J, Krakowski K, et al. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob Agents Chemother 2000, 44:2475-2684.